The “Therapeutic Applications” pre-review provides detail regarding the therapeutic applications of cannabis. In one survey, the top five medical conditions for which cannabinoids were employed as treatment were back pain, sleep disorders, depression, post-injury pain, and multiple sclerosis. Several member states have medicinal cannabis laws in place and in which cannabis can be obtained for medical reasons including Canada, The Netherlands, Israel, Australia, Argentina, Austria, Chile, Colombia, the Czech Republic, Denmark, Germany, Guam, Portugal, Puerto Rico, Italy, Uruguay, and Jamaica. Cannabis is illegal and not approved at the federal level formedicinal applications in the U.S.A., although 29 states and the District of Columbia have medicinal laws in place.
The pre-review found varied efficacy of cannabis for a variety of clinical ailments when limited to randomized clinical trials. In a trial of 67
partic ipants with HIV infection, dronabinol and smoked cannabis produced significantly greater weight gain than placebo and were found safe. Multiple randomized, controlled clinical trials show cannabis as an effective analgesic although most of these used plant-derived cannabinoids. Importantly, a placebo-controlled trial of inhaled aerosolized cannabis demonstrated a dose-dependent reduction in spontaneous pain ratings in diabetic patients suffering from peripheral neuropathy that had been treatment-refractory.
Three randomized controlled trials have shown smoked cannabis to be an effective treatment for neuropathic pain.Two open-labeled, uncontrolled, observational studies of smoked cannabis or vaporized cannabis reported significantly decreased motor disability and pain scores in Parkinson’s patients
e.Need of the substance for other purposes (e.g. industrial)
Low potency (0.2% to 0.3%△9-THC) cannabis (hemp) is cultivated to produce paper, textiles, rope or twine, and construction materials based on fiber from stalks. Grain from industrial hemp is used in food products, cosmetics, plastics and fuel.
f. Measures taken by countries to curb misuse
This topic appears not to be addressed in the component pre-reviews. At the time of this peer review (20180521), the Annex was not available for evaluation in this regard.
g.Impact if this substance is scheduled
The impact of continued scheduling of cannabis was not addressed in any of the component pre-reviews.
2.Are there absent data that would be determinative for scheduling?
It would be helpful in a future expanded review of cannabis to have comparisons of cannabis effects and abuse and its related disorders with synthetic cannabinoid effects and abuse and their related disorders.
Although cannabis is currently scheduled within The Single Convention on Narcotic Drugs, 1961, and the synthetic cannabinoids have been scheduled in recent years in The Convention on Psychotropic Substances, 1971, to obtain a more holistic vision of the possibilities how cannabis should be controlled or not it would be informative to have these comparisons.